US4284641A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutically active imidazole derivatives
Assignee: SmithKline Beecham Corp
•
Filing: 1978-08-24
•
Granted: 1981-08-18
•
Expires: 1998-08-24
Abstract
Abstract The invention relates to a class of imidazoles substituted by cycloalkyl or cycloalkenyl which have pharmacological properties making them useful in medicine, in particular in the prophylaxis and treatment of thrombo-embolic disorders.
Inventors
- 👤 Peter B. Thorogood
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 15:15
CPC Classifications
C; C07; C07D; C07D231/00; C07D231/02; C07D231/10; C07D231/12; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/435; A61K31/44; A61K31/445; A61K31/47; A61K31/485; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/535; A61K31/55; A61P; A61P7/00; C07C; C07C17/00; C07C17/093; C07C17/16; C07D233/00; C07D233/54; C07D233/56; C07D233/66; C07D233/84; C07D249/00; C07D249/02; C07D249/08; C07D319/00; C07D319/10; C07D319/14; C07D319/16; C07D319/20
Claims Analysis
Total Claims: 93
Claim 1
Independent Claim
144 words
A method for the treatment or prophylaxis of a thrombo-embolic disorder of a mammal or a mammalian tissue comprising the administration to the mammal or mammalian tissue of a non-toxic, anti-thrombo-embolic amount of an imidazole of the formula ##STR8## in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms and optionally substituted by one two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form an alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical of from 4 to 9 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
144 words
A method for the treatment or prophylaxis of a thrombo-embolic disorder of a mammal or a mammalian tissue comprising the administration to the mammal or mammalian tissue of a non-toxic, anti-thrombo-embolic amount of an imidazole of the formula ##STR8## in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms and optionally substituted by one two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form an alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical of from 4 to 9 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
75 words
A method as claimed in claim 1 wherein n is 1, A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
41 words
A method as claimed in claim 1 wherein n is 1, A is selected from --CH 2 -- and --(CH 2 ) 2 -- and R is selected from a cycloalkyl or cycloalkenyl radical containing from 6 to 8 carbon atoms.
Claim 5
Dependent Claim
25 words
A method as claimed in claim 1 wherein the imidazole is selected from 1-cyclooctylmethylimidazole, 1-cyclohexylethylimidazole and 1-cyclohex-3-enylmethylimidazole, 1-cycloheptylmethylimidazole, and pharmaceutically acceptable acid addition salts thereof.
Claim 6
Dependent Claim
22 words
A method as claimed in claim 1 wherein the imidazole or a pharmaceutically acceptable salt thereof is administered orally to a mammal.
Claim 7
Dependent Claim
22 words
A method as claimed in claim 1 wherein the imidazole or a pharmaceutically acceptable salt thereof is administered parenterally to a mammal.
Claim 8
Dependent Claim
19 words
A method as claimed in claim 1 wherein the mammal or mammalian tissue is man or human tissue respectively.
Claim 9
Dependent Claim
46 words
A method as claimed in claim 1 wherein the imidazole or a pharmaceutically acceptable salt thereof is administered to a mammal in an amount of from 0.1 to 300 mg per kg body weight of mammal, said amount of dose being the amount of imidazle base.
Claim 10
Dependent Claim
27 words
A method as claimed in claim 8 wherein the amount is from 0.5 to 10.0 mg per kg body weight of mammal, said dose calculated as base.
Claim 11
Dependent Claim
14 words
A method as claimed in claim 1 comprising the treatment or prophylaxis of thrombosis.
Claim 12
Dependent Claim
15 words
A method as claimed in claim 1 comprising the treatment or prophylaxis of cerebro-vascular thrombosis.
Claim 13
Dependent Claim
15 words
A method as claimed in claim 1 comprising the treatment or prophylaxis of myocardial infarction.
Claim 14
Dependent Claim
16 words
A method as claimed in claim 1 comprising the treatment or prophylaxis of peripheral vascular disease.
Claim 15
Independent Claim
37 words
A method for the treatment or prophylaxis of a thrombo-embolic disorder of a mammal including man comprising the administration to the mammal of a non-toxic, anti-thrombo-embolic amount of 1-cyclooctylmethylimidazole or a pharmaceutically acceptable acid addition salt thereof.
Claim 16
Independent Claim
37 words
A method for the treatment or prophylaxis of a thrombo-embolic disorder of a mammal including man comprising the administration to the mammal of a non-toxic, anti-thrombo-embolic amount of 1-cyclooctylmethylimidazole or a pharmaceutically acceptable acid addition salt thereof.
Claim 17
Dependent Claim
14 words
A method as claimed in claim 14 wherein the thrombo-embolic disorder is myocardial infarction.
Claim 18
Dependent Claim
14 words
A method as claimed in claim 14 wherein the thrombo-embolic disorder is cerebro-vascular thrombosis.
Claim 19
Dependent Claim
16 words
A method as claimed in claim 14 wherein the thrombo-embolic disorder is ischaemic peripheral vascular disease.
Claim 20
Dependent Claim
138 words
A pharmaceutical formulation, for the treatment or prophylaxis of a thrombo-embolic disorder in a mammal comprising a non-toxic, anti-thrombo-embolic amount of an imidazole of the formula ##STR9## in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms and optionally substituted by one, two, three or more alkyl radicals and containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form n alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical from 4 to 9 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier therefor.
Claim 21
Dependent Claim
138 words
A pharmaceutical formulation, for the treatment or prophylaxis of a thrombo-embolic disorder in a mammal comprising a non-toxic, anti-thrombo-embolic amount of an imidazole of the formula ##STR9## in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms and optionally substituted by one, two, three or more alkyl radicals and containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form n alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical from 4 to 9 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier therefor.
Claim 22
Dependent Claim
83 words
A pharmaceutical formulation as claimed in claim 18 wherein n is 1, A is a straight or branched saturated or unsaturated acyclic hydrocarbon radical of from 1 to 3 carbon atoms and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, the imidazole being the free base or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier therefor.
Claim 23
Dependent Claim
41 words
A pharmaceutical formulation as claimed in claim 18 wherein n is 1, R is selected from a cycloalkyl and a cycloalkenyl radical of from 6 to 8 carbon atoms, and A is --CH 2 -- or --(CH 2 ) 2 --.
Claim 24
Dependent Claim
27 words
A pharmaceutical formulation as claimed in claim 18 wherein the imidazole is selected from 1-cyclooctylmethylimidazole, 1-cyclohexylethylimidazole, 1-cycloheptylmethylimidazole and 1-cyclohex-3-enylmethylimidazole and pharmaceutically acceptable and acid addition salts thereof.
Claim 25
Dependent Claim
18 words
A pharmaceutical formulation as claimed in any of claims 18 to 21 in the form of a tablet.
Claim 26
Dependent Claim
23 words
A pharmaceutical formulation as claimed in any of claims 18 to 21 in the form of a parenterally acceptable injectable solution or suspension.
Claim 27
Dependent Claim
18 words
A pharmaceutical formulation as claimed in any of claims 18 to 21 in the form of a capsule.
Claim 28
Dependent Claim
38 words
A pharmaceutical formulation for the treatment or prophylaxis of a thrombo-embolic disorder in a mammal comprising a non-toxic, anti-thrombo-embolic amount of 1-cyclooctylmethylimidazole or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier therefor.
Claim 29
Dependent Claim
38 words
A pharmaceutical formulation for the treatment or prophylaxis of a thrombo-embolic disorder in a mammal comprising a non-toxic, anti-thrombo-embolic amount of 1-cyclooctylmethylimidazole or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier therefor.
Claim 30
Dependent Claim
27 words
A tablet for the treatment or prophylaxis of a thrombo-embolic disorder in a mammal having a non-toxic, anti-thrombo-embolic amount of 1-cyclooctylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 31
Dependent Claim
27 words
A tablet for the treatment or prophylaxis of a thrombo-embolic disorder in a mammal having a non-toxic, anti-thrombo-embolic amount of 1-cyclooctylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 32
Dependent Claim
30 words
A tablet as claimed in claim 26 containing from 50 to 600 mg of the imidazole or a pharmaceutically acceptable salt thereof, said amount being calculated as the free base.
Claim 33
Dependent Claim
13 words
A tablet as claimed in claim 27 wherein the amount is 150 mg.
Claim 34
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-Cyclohexylethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 35
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-Cyclopentylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 36
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thrombo-embolic amount 1-Cyclooctylvinylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 37
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thrombo-embolic amount 1-Cyclooctylvinylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 38
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-Cyclooctylethyl) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 39
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-Cyclooctylethyl) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 40
Dependent Claim
36 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-(2-Cycoolctylethyl) imidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 41
Dependent Claim
36 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-(2-Cycoolctylethyl) imidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 42
Dependent Claim
36 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-(3-Cyclooctylpropyl) imidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 43
Dependent Claim
36 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-(3-Cyclooctylpropyl) imidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 44
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-(Cycloheptylmethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 45
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-Cyclononylmethylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 46
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-Cyclononylmethylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 47
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-(4-Methylcyclohexylmethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 48
Dependent Claim
36 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-(Cyclobutylmethyl) imidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 49
Dependent Claim
36 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-(Cyclobutylmethyl) imidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 50
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-Cyclohexylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 51
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-n-Butylimidazole or a pharmaceutically acceptable salt thereof.
Claim 52
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-n-Pentylimidazole or a pharmaceutically acceptable salt thereof.
Claim 53
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-n-Hexylimidazole or a pharmaceutically acceptable salt thereof.
Claim 54
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-(3-Methylbutyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 55
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-Cyclohex-3-enylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 56
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-(Cyclohept-2-enylmethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 57
Dependent Claim
64 words
A pharmaceutical preparation in dosage unit form adapted for administration to obtain an anti-thrombo-embolic effect, comprising, per dosage unit, an anti-thrombo-embolic-effective non-toxic amount of a compound selected from the group consisting of 1-Cyclooctylmethylimidazole 1-Cyclohex-3-enylmethylimidazole 1-Cyclohexylethylimidazole 1-Cyclopentylmethylimidazole 1-Cyclooctylvinylimidazole 1-(1-Cyclooctylethyl)imidazole 1-(2-Cyclooctylethyl)imidazole 1-(3-Cyclooctylpropyl)imidazole 1-(Cycloheptylmethyl)imidazole 1(Cyclohept-2-enylmethyl)imidazole 1-Cyclonoylmethylimidazole 1-(4-Methylcyclohexylmethyl)imidazole 1-(Cyclobutylmethyl)Imidazole 1-Cycloheptylimidazole 1-Cyclopentylimidazole 1-Cyclohexylmethylimidazole 1-n-Butylimidazole 1-n-Pentylimidazole 1-n-Hexylimidazole 1-Pent-2-enylimidazole 1-Pent-4-enylimidazole 1-(3-Methylbutyl)imiazole and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
Claim 58
Dependent Claim
64 words
A pharmaceutical preparation in dosage unit form adapted for administration to obtain an anti-thrombo-embolic effect, comprising, per dosage unit, an anti-thrombo-embolic-effective non-toxic amount of a compound selected from the group consisting of 1-Cyclooctylmethylimidazole 1-Cyclohex-3-enylmethylimidazole 1-Cyclohexylethylimidazole 1-Cyclopentylmethylimidazole 1-Cyclooctylvinylimidazole 1-(1-Cyclooctylethyl)imidazole 1-(2-Cyclooctylethyl)imidazole 1-(3-Cyclooctylpropyl)imidazole 1-(Cycloheptylmethyl)imidazole 1(Cyclohept-2-enylmethyl)imidazole 1-Cyclonoylmethylimidazole 1-(4-Methylcyclohexylmethyl)imidazole 1-(Cyclobutylmethyl)Imidazole 1-Cycloheptylimidazole 1-Cyclopentylimidazole 1-Cyclohexylmethylimidazole 1-n-Butylimidazole 1-n-Pentylimidazole 1-n-Hexylimidazole 1-Pent-2-enylimidazole 1-Pent-4-enylimidazole 1-(3-Methylbutyl)imiazole and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
Claim 59
Dependent Claim
30 words
A pharmaceutical preparation as recited in claim 46 wherein the amount of said compound is within the range from about 50 to about 600 milligrams, said amount calculated as base.
Claim 60
Dependent Claim
147 words
A pharmaceutical preparation in dosage unit form adapted for administration to obtain an anti-thrombo-embolic effec, comprising, per dosage unit, an anti-thrombo-embolic-effective non-toxic amount of an compound selected from the group consisting of an imidazole of the formula ##STR10## in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of form 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms and optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form an alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical of from 4 to 9 carbon atoms, the imidazole being the free base and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
Claim 61
Dependent Claim
147 words
A pharmaceutical preparation in dosage unit form adapted for administration to obtain an anti-thrombo-embolic effec, comprising, per dosage unit, an anti-thrombo-embolic-effective non-toxic amount of an compound selected from the group consisting of an imidazole of the formula ##STR10## in which A is a straight or branched, saturated or unsaturated acyclic hydrocarbon radical of form 1 to 3 carbon atoms, n is 0 or 1, and R is a cycloalkyl or cycloalkenyl radical of from 4 to 9 carbon atoms and optionally substituted by one, two, three or more alkyl radicals each containing from 1 to 4 carbon atoms, or, when n is 1, A and R together form an alkyl radical of from 4 to 7 carbon atoms or an alkenyl or alkynyl radical of from 4 to 9 carbon atoms, the imidazole being the free base and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
Claim 62
Dependent Claim
30 words
A pharmaceutical preparation as recited in claim 48, wherein the amount of said compound is within the range from about 50 to about 600 milligrams, said amount calculated as base.
Claim 63
Dependent Claim
37 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti thromo embolic amount 1-Cyclohex-e-enylmethylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 64
Dependent Claim
37 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti thromo embolic amount 1-Cyclohex-e-enylmethylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 65
Dependent Claim
36 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-(Cyclohept-2-enylmethyl) imidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 66
Dependent Claim
36 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-(Cyclohept-2-enylmethyl) imidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 67
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-Pent-2-enylimidazole or a pharmaceutically acceptable salt thereof.
Claim 68
Dependent Claim
17 words
The pharmaceutical formulation of claim 18 wherein said imidazole is 1-Pent-4-enylimidazole or a pharmaceutically acceptable salt thereof.
Claim 69
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-cyclopentylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 70
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-cyclopentylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 71
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-cycloheptylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 72
Dependent Claim
35 words
A pharmaceutical formulation for the treatment or prophylaxis of a thromo-embolic disorder in a mammal comprising a non-toxic, anti-thromo-embolic amount 1-cycloheptylimidazole or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier therefor.
Claim 73
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-Cyclohex-3-enylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 74
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-cyclohexylethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 75
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-cyclopentylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 76
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-cyclooctylvinylimidazole or a pharmaceutically acceptable salt thereof.
Claim 77
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-(1-Cyclooctylethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 78
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-(2-Cyclooctylethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 79
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-(3-Cyclooctylpropyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 80
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-(Cycloheptylmethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 81
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-(Cyclohept-2-enylmethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 82
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-Cyclononylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 83
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-(4-Methylcyclohexylmethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 84
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-(Cyclobutylmethyl)imidazole or a pharmaceutically acceptable salt thereof.
Claim 85
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-Cycloheptylimidazole or a pharmaceutically acceptable salt thereof.
Claim 86
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-Cyclopentylimidazole or a pharmaceutically acceptable salt thereof.
Claim 87
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-Cyclohexylmethylimidazole or a pharmaceutically acceptable salt thereof.
Claim 88
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-n-Butylimidazole or a pharmaceutically acceptable salt thereof.
Claim 89
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-n-Pentylimidazole or a pharmaceutically acceptable salt thereof.
Claim 90
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-n-Hexylimidazole or a pharmaceutically acceptable salt thereof.
Claim 91
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-Pent-2-enylimidazole or a pharmaceutically acceptable salt thereof.
Claim 92
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-Pent-4-enylimidazole or a pharmaceutically acceptable salt thereof.
Claim 93
Dependent Claim
16 words
The method of claim 1, wherein the imidazole is 1-(3-Methylbutyl)imidazole or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
DE1213413B
Cited
NL6706104A
Cited
GB1122717A
Cited
BE719664A
Cited
US3541109A
Cited
US3637731A
Cited
FR1603793A
Cited
US3843676A
Cited
GB1364312A
Cited
US4006243A
Cited
US3927017A
Cited
US3991201A
Cited
DE2533211A1
Cited
US4036975A
Cited
US4115578A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-08-17 | 1985-02-16 | 1985-08-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-08-17 | 1989-02-16 | 1989-08-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-08-17 | 1993-02-16 | 1993-08-18 | $7700.00 | Window Closed / Lapsed |